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Abstract. We describe the design and use of repair-PPRHs and 
editing-PPRHs as a new methodology either to correct a point 
mutation or to edit a genomic fragment of the dihydrofolate reductase 
gene in Chinese Hamster Ovary (CHO) cells. Repair-PPRHs are 
formed by a PPRH core, following the Reverse Hoogsteen bonds 
rules, covalently connected to a repair tail, which is homologous 
to the mutated region of the dsDNA except for the repaired 
nucleotide. Several point mutations in the endogenous dhfr gene 
have been successfully repaired in mammalian cells using                       
repair-PPRHs, including a deletion, an insertion, and single and 
double substitutions in different regions of the gene. All repaired 
colonies showed high levels of DHFR protein and activity, and the 
corrected nucleotide was confirmed in all DNA sequences. 
Editing-PPRHs are formed by a PPRH core, covalently connected 
to a sequence tail homologous to the upstream and downstream 
regions of the DNA fragment to be edited. All edited colonies 
showed high levels of DHFR protein and activity, and the edition 
was confirmed in all DNA sequences.       
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Introduction 
  
 Mutations are a natural process that alters the DNA and are constantly 
taking place in the genome. It is estimated that tens of thousands of changes 
happen daily in the DNA of a human cell [1]. Not all the mutations result in 
functional impairment, but in some cases, small changes in the DNA 
sequence can provoke an enormous impact on an entire living being. 
Therefore, these mutations need to be reversed by the DNA repair machinery 
that fixes DNA damage such as mismatched nucleotides, DNA cross-links, 
bulky adducts and splicing broken DNA strands back together.  
 Depending on the cells affected, mutations can be classified in two 
groups: inherited mutations, when they affect germ cells, and the alteration 
can often be passed on to offspring; and acquired mutations, that can 
spontaneously arise during the life of an organism in somatic cells. 
Mutations of the latter can result from normal metabolic activities including 
DNA replication errors, spontaneous lesions such as depurination and 
deamination of the DNA, and the generation of reactive oxygen species 
(ROS), but can also result from environmental factors such as physical or 
chemical mutagens [2–4] (Fig. 1). 
 Point mutations are a type of mutations that typically refer to an 
alteration of a single or a few adjacent base pairs in a DNA sequence. They 
usually take place during DNA replication, although other endogenous and  
 
 
 
Figure 1. Causes of DNA damage. 
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exogenous agents can be implicated. Some point mutations are beneficial or  
have no effect. Polymorphisms for instance, are mutations that generally do 
not cause functional damage under basal conditions. Nonetheless, these 
alterations can also be detrimental for gene function at various levels. If the 
mutation occurs in the promoter region of a gene, the expression of this gene 
may be altered. If the alteration is caused in a coding region, the activity may 
change and in the case of insertions or deletions a frame shift can be 
produced, thus changing the whole peptide or provoking the appearance of a 
nonsense mutation originating a truncation of the protein. In addition, if the 
mutated base pair is found near or in the intron-exon junction, it can result in 
a splicing alteration of the mRNA.  
 DNA damage may lead towards a large variety of lesions, including 
mismatches, chemical adducts or single- and double-strand breaks (DSBs). 
Therefore, different repair pathways have evolved, each focused on a 
particular type of lesion.  
 If DNA damage affects terminally differentiated cells, DNA damage 
repair will ensure the integrity of the transcribed genome. However, if 
DNA damage occurs in dividing cells, “cell cycle checkpoints” will detect 
the damage by sensor proteins, and by means of different protein 
complexes, signal transducers and effector proteins. These effector 
proteins will lead to the repair of DNA or will temporarily stop the 
proliferating cells in their cell cycle progression to provide enough time to 
the DNA repair machinery to act. Some of these important cell cycle 
checkpoint proteins are ataxia telangiectasa mutated (ATM) and ATM and 
Rad3 related (ATR) that act as signal transducers. In response to DNA 
damage in G1, for example, these proteins will phosphorylate p53, which 
acts as a transcription factor for p21, leading to an inhibition of both 
cyclinE/Cdk2 and cyclinA/Cdk2 complexes, and therefore an inhibition of 
G1/S transition, thus preventing the synthesis of damaged DNA [5–8]. 
However, the specific pathway that will be activated is determined by the 
type of DNA damage. When repair processes fail and DNA damage cannot 
be repaired, cells may become senescent or can be conducted to 
programmed cell death or apoptosis. Apoptosis is conducted by different 
protein factors such as the anti-apoptotic protein Bcl-2, inhibited directly 
or indirectly by p53 [9]. If any of these processes do not work properly, 
there may be an unregulated cell division that can lead to the formation of 
a tumor, which could become cancerous.  
 DNA damage checkpoints can halt cell proliferation, but the repair 
machinery is required to prevent the transduction of mutations to daughter 
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cells. DNA-damage-signaling and DNA repair are believed to be linked and 
operate collectively [10,11]. As mentioned before, since there is a wide 
diversity of possible lesions, a large variety of DNA repair mechanisms have 
evolved, such as direct reversal repair, base excision repair (BER), 
nucleotide excision repair (NER), mismatch repair (MMR), and DSB repair 
(Fig. 2).  
 Gene augmentation therapy (GAT) is one of the most studied 
strategies to treat diseases caused by point mutations; it consists of 
introducing copies of the wild type gene in the affected cells to obtain the 
functional protein in sufficient amounts to restore the normal phenotype. 
This strategy is especially available for recessive diseases, since the 
mutated gene does not interfere with the normal product, and the amount 
of this product does not need a rigorous regulation to recover a normal 
phenotype. However, it presents some drawbacks, as random gene 
integration in the genome, and the loss of endogenous regulator elements 
of the gene. As an alternative, a different philosophy for gene repair was 
developed to correct point mutations in their endogenous loci using 
different types of oligonucleotides. These strategies consisted of targeting  
 
 
 
Figure 2. Scheme of DNA repair responses. 
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the genomic DNA with an oligonucleotide complementary to the                 
DNA sequence, except for the corrected nucleotide. In the last years, different 
approaches have emerged in this direction, such as chimeric RNA-DNA 
oligonucleotides, single-stranded oligonucleotides (ssOs), bifunctional 
triple-helix-forming oligonucleotides (TFBO), or peptide nucleic acids 
(PNAs). 
 Programmable endonucleases such as zinc-finger nucleases (ZFN), 
transcription activator-like effector nucleases (TALENs) and Clustered 
Regulatory Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-
associated 9 (Cas9), are artificial proteins composed of a sequence specific 
DNA-binding domain fused to a nuclease, that are able to provoke double 
strand breaks (DSBs) in the genome, thus stimulating the cellular DNA 
repair-mechanisms, including error-prone non-homologous end joining 
(NHEJ), in the absence of a homologous DNA template, and homologous 
recombination (HR), in the presence of a synthetic repair template [12]. 
These site-specific nucleases have shown to edit DNA to disrupt, introduce, 
invert, or delete genes [13]. Although to a lesser extend, these tools are also 
being studied to correct point mutations [13,14]. 
 
1. Polypurine reverse Hoogsteen Hairpins 
 
 PPRHs are non-modified DNA molecules formed by two antiparallel 
polypurine strands linked by a pentathymidine loop that allows the 
formation of intramolecular reverse-Hoogsteen bonds between both 
strands. These hairpins bind to polypyrimidine stretches in the DNA via 
Watson-Crick bonds, while maintaining the hairpin structure (Fig. 3). It 
was demonstrated that PPRHs, upon binding their polypyrimidine target in 
a dsDNA, were able to displace the polypurine strand of the target duplex 
configuration [15,16]. 
 Because the polypyrimidine domains can be found in both strands of the 
DNA, PPRHs can be designed to target either one of the strands of genomic 
DNA. PPRHs directed against the template strand of the DNA are called 
template-PPRHs, while the ones targeting the coding strand of the DNA are 
called coding-PPRHs, which are also able to bind transcribed mRNA, since 
it has the same sequence and orientation than the coding strand of the DNA. 
Therefore, PPRHs can act as antigene and antisense oligonucleotides 
depending on the strand they target (Fig. 4). PPRHs were first described for 
gene silencing [15–20]. 
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Figure 3. PPRH characteristics and structure. 
 
    
 
 
 
Figure 4. PPRHs for gene silencing. 
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2. Repair-PPRHs 
 
 Repair-PPRHs are Polypurine reverse Hoogsteen hairpins bearing an 
extension sequence at one end homologous to the DNA strand to be repaired 
but containing the wild type nucleotide instead of the mutation. We made a 
successful first attempt to correct a point mutation at the endogenous locus 
of the dhfr gene. Homologous recombination was found to play an important 
role in the mechanism for gene correction by repair-PPRHs [21]. 
 Next we wanted to expand the use of repair-PPRHs and improve the 
methodology to correct a representative collection of different types of 
mutations (substitutions, double substitutions, deletions, and insertions) at an 
endogenous locus in a mammalian genome. To achieve this goal, we again 
used the dhfr gene as a model because it is a selectable marker that readily 
allows for the identification of repaired clones, and because of the 
availability of an extensive collection of endogenous mutants obtained by 
UV irradiation, and different chemicals such as N-hydroxy-aminofluorene 
[22–26]. 
 To test the potential of repair-PPRHs in different types of point 
mutations, we used a collection of various dhfr mutant cells; all derived  
from the parental cell line UA21 [27], which carries only one copy of the dhfr  
 
Table 1. Compendium of different mutant cell lines subjected to correction using 
Repair-PPRHs. 
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gene. The natural stop codon is found at nucleotide 562 of the protein-coding 
region. All mutants produce termination codons either by a direct base 
substitution or indirectly due to frame shift by single base insertions or 
deletions or by exon skipping (Table 1). These mutant cells produce no 
functional DHFR enzyme and so are unable to grow in a DHFR selective 
culture medium without glycine, hypoxanthine and thymidine (-GHT).   
 Table 1 shows the characteristics of the different cell lines subjected to 
correction with Repair-PPRHs. The mutated bases are represented in the 
coding strand with a 5' to 3' orientation. Position numbers are referred to the 
translational initiation site (ATG). For mutations that occurred in introns, the 
position relative to the nearest exon is given, where + indicates downstream 
of the exon and - means upstream of the exon. 
 Specific repair-PPRHs for each mutant cell line were devised by 
attaching to the end of one strand of the PPRH core, a sequence tail 
homologous to the point mutation region of the target, except for the mutated 
nucleotide, which was corrected (Table 2). This extended tail was added              
to provide the PPRHs with the ability to repair the mutation. We searched for  
 
Table 2. Sequences of the repair-PPRHs against the dhfr gene. 
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polypyrimidine regions near to the point mutations and proceeded according 
to the rules of PPRH construction [16,17]. When encountering purine 
interruptions in the polypyrimidine stretches, we chose the WT-PPRH 
strategy, which includes the base complementary to the target interruption in 
the PPRH core [28].  
 Table 2 shows the names and sequences of the repair-PPRHs as well as 
the cell line used. The corresponding corrected nucleotide in the                      
repair-PPRHs is shown in bold and bigger size. Bulleted symbols represent 
reverse-Hoogsteen bonds. 
 In all of the experiments, DHFR mRNA levels, protein levels, enzyme 
activity levels and DNA sequences were determined as follows. Different 
numbers of cells, ranging from 1,000 to 150,000 were plated and the 
corresponding repair-PPRHs were transfected using 2 to 5 µg of DNA. Six 
random cell colonies surviving in –GHT medium from different experiments 
were expanded individually, and the targeted DNA region was                    
PCR-amplified and sequenced. Cells were subsequently analyzed for DHFR 
mRNA, protein, and enzyme activity levels. DHFR protein levels in the 
repaired cells were measured by Western blot performed with 100 µg of total 
protein extracts and were normalized to tubulin levels. Protein levels in the 
repaired colonies were referred to those of the positive control UA21. DHFR 
activity was determined by the incorporation of 2 µCi of 6-[
3
H] deoxyuridine 
to the DNA. Cells were collected and lysed with SDS after 24 h. 
Radioactivity was counted in a scintillation counter. DHFR mRNA levels 
were measured using qRT-PCR and were normalized to APRT. DHFR 
mRNA levels of the repaired colonies were also referred to the positive 
control UA21. 
 
3. Correction of single point mutations using Repair-PPRHs 
 
 The first cell line subjected to correction by repair-PPRHs was DA5, 
where the deletion of a guanine in exon 6 of the dhfr gene results in a frame 
shift that generates a premature opal stop codon (TGA). The                  
repair-PPRH used (HpDE6rep) contained three pyrimidine interruptions, and 
its hairpin core was extended with 25nt at the 5’ end including the missing 
guanine. We confirmed the presence of the corrected nucleotide in all 
repaired colonies analyzed. DHFR mRNA levels in the repaired cells were 
higher than in the mutant DA5 cell line. The protein was restored in all 
cases, and it showed high levels of DHFR activity (Fig. 5). The next step 
was to test whether repair-PPRHs were also able to correct substitutions. 
Thus, we chose DA7 cells that contain a substitution of a guanine                        
by a thymine in exon 3, producing an amber stop codon (TAG) in situ. A 20nt  
Carles Ciudad et al. 60 
 
 
 
 
Figure 5. Correction of a deletion, a substitution and an insertion in dhfr mutant cell 
lines. DHFR protein levels, DHFR activity, DHFR mRNA levels and DNA 
sequences in repaired cells are shown. UA21 cells bearing a copy of the dhfr wild 
type gene are used as a positive control whereas the mutant cell line corresponds to 
the negative control. 
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polypyrimidine sequence in the template strand upstream of the point 
mutation was used to design HpDE3rep. The sequence tail was extended 
from the 3’ end of the hairpin core, with the wild type guanine instead of the 
thymine present in the mutant. After the isolation of the surviving colonies, 
we confirmed the corrected guanine in the DNA sequence, high levels of 
mRNA, protein, and activity compared to DA7 cells (Fig. 5).  
 Insertions are another type of point mutation very detrimental due to the 
disruption of the reading frame of a sequence. We chose the DI33A cell line 
to test whether repair-PPRHs were able to correct an insertion of a guanine 
in dhfr exon 6. Two repair-PPRHs were designed.  
 HpDE6-4rep using a 14nt pyrimidine sequence found in the coding 
strand upstream of the mutation, and HpDE6-5rep using a 15nt sequence in 
the template strand downstream of the mutation. Both repair-PPRHs 
succeeded in correcting the mutation by introducing the missing guanine in 
the DNA sequence, and thus restoring DHFR protein and its activity [29]. 
The amount of DHFR mRNA of repaired cells was similar to those of the 
mutant cells (Fig. 5). 
 Substitutions can also be found in non-coding regions, without changes 
in the amino acid sequence. However, an alteration in an intron may affect 
splicing and lead to a frame shift in the subsequent downstream amino acid 
sequence. Hence, the DP12B mutant cell line was chosen to test the capacity 
of repair-PPRHs to correct a substitution of an adenine by a thymine at the 
penultimate position of intron 4 that causes the skipping of exon 5 and a 
subsequent opal premature stop codon in exon 6. We searched for 
polypyrimidine sequences in both DNA strands near the point mutation, 
finding different domains. HpDI4-2rep originated from a 13nt 
polypyrimidine sequence in the template strand, 18nt upstream of the 
mutation. The second repair-PPRH target was 22nt, contained one purine 
interruption and was found 41nt upstream of the mutation. In this case, it 
was not feasible to design a repair tail directly attached to the hairpin core, 
because the total repair-PPRH sequence would exceed a length of 100nt in 
the synthesis of oligonucleotides. Therefore, we attempted a different design 
in which the hairpin core and the repair tail were connected by 5 thymidines 
instead of the whole intervening sequence between them. This PPRH was 
called SDR-HpDI4-3rep, for Short-Distance-Repair hairpin, since it skipped 
26 nucleotides of the intron. Upon transfection, surviving colonies were 
obtained in selective medium with HpDI4-2rep and SDR-HpDI4-3rep. These 
colonies were isolated and analyzed, and DHFR mRNA levels were 
comparable to the mutant cells. The DNA sequence was corrected and the 
protein was restored showing DHFR activity (Fig. 6) [29]. 
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 Our results showed that repair-PPRHs could correct different types of 
single nucleotide mutations. The next challenge would be to repair double 
point mutants. Thus, DU8 cells were selected to test the ability of                  
repair-PPRHs to correct the tandem mutation of two nucleotides. DU8 cells 
contain a substitution of 2 nucleotides, Gg > Aa, involving the last 
nucleotide of exon 2, and the first nucleotide of intron 2. This change does 
not involve a nonsense mutation in situ, but provokes the skipping of exon 2, 
which disrupts the reading frame. As a consequence, an opal stop codon 
appears prematurely. Two different repair-PPRHs were designed for this 
approach: HpDE2-1rep, located 7nt upstream of the mutation, and                  
HpDE2-2rep, 12nt downstream of the mutation. The structure of HpDE2-1rep 
is that of a hairpin core of 13nt, containing two pyrimidine interruptions, 
followed by a 24nt tail bearing the corrected nucleotides. In HpDE2-2rep the 
hairpin core contains 10nt, with one interruption, ending in a 25nt repair tail. 
Both repair-PPRHs succeeded in correcting the double point mutation at all 
levels (Fig. 6) [29].  
 
 
 
Figure 6. Correction of a substitution in an intron and a double substitution in dhfr 
mutant cell lines. DHFR protein levels, DHFR activity, DHFR mRNA levels and 
DNA sequences in repaired cells are shown. Experimental conditions are the same as 
described before. UA21 cells bearing a copy of the dhfr wild type gene are used as a 
positive control whereas the mutant cell line corresponds to the negative control. 
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 One of the limitations of this methodology could reside in finding 
homopurine domains relatively close to the point mutation. To solve this, 
we designed a Long Distance Repair-PPRH (LDR-PPRH) which contains a 
hairpin core hundreds of nucleotides away from the location of the 
mutation, linked by 5 Ts to the repair tail. This approach was tested in 
DF42 cells, containing a substitution of a guanine by a thymine in exon 6 
resulting in an ochre stop codon (TAA). We designed a repair tail at the 
location of the point mutation, and a hairpin core targeting a sequence 
located 662nt downstream. This repair-PPRH was called LDR-HpDE6-1rep, 
formed by a hairpin core of 22nt in each homopurine strand containing 
three pyrimidine interruptions, and a tail of 31nt. In parallel, we also tested 
HpDE6rep, a regular repair-PPRH, and we obtained similar results 
 
 
 
Figure 7. Correction of a G substitution in DF42 cell line. DHFR protein levels, 
DHFR activity, DHFR mRNA levels, and DNA sequences in repaired cells are 
shown. Experimental conditions are the same as described before. UA21 cells 
bearing a copy of the dhfr wild type gene are used as a positive control whereas the 
mutant cell line corresponds to the negative control. 
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for both approaches. The levels of mRNA in the repaired cells were similar 
to those of the mutant. However, repaired colonies recovered DHFR protein 
with high activity, and the nucleotide was corrected in the DNA sequence 
(Fig. 7) [29].  
 
4. Editing-PPRHs 
 
 Duchenne muscular dystrophy (DMD) is a progressive and fatal 
degenerative muscle disease caused by mutations due to large deletions 
(approx. 65%) in the DMD gene encoding for the dystrophin protein. 
Accordingly, the resulting reading frame involves an aberrant dystrophin 
translation, causing the absence of the protein essential for the muscle. This 
leads to an irreversible damage of muscle fibers that are replaced by adipose 
tissue. A variant of the disease, the Becker muscular dystrophy (BMD), 
results in a much milder phenotype. This disease is also caused by mutations 
in the dystrophin gene, but they do not completely disrupt the reading frame 
of the protein, and thus allow the production of a reduced version of a 
partially functional protein. In DMD one or several exons are deleted, and 
this mutation interferes with the assembly of the full-length mRNA. This 
fact led to the development of a therapeutic strategy for DMD called "exon 
skipping strategy", in which antisense deoxyoligonucleotides (aODNs) are 
used to mediate the elimination of the mutated exon, alone or with additional 
adjacent exons, to restore the reading frame of the protein. In these 
conditions, the expression of a shorter but functional dystrophin protein is 
induced, simulating the BMD phenotype [30]. Theoretically, exon skipping 
could be used to treat approximately 90%, 80%, and 98% of DMD patients 
with deletion, duplication, and nonsense mutations, respectively [31]. 
Several aODNs developed using different chemical modifications such as 
2'OMethyl (Prosensa Inc., Switzerland) and morpholinos (PMOs)                 
(AVI Biopharma, UK) are currently in Phase II or Phase III trials to validate 
the effectiveness of this therapeutic approach. 
 In order to explore the capability of PPRHs to cause Exon-skipping at 
the DNA level to be applied to the DMD gene as a possible therapeutic tool, 
we probed the potential of PPRHs for this purpose using a gene with a clean 
metabolic selection. In this regard, the editing abilities of PPRHs were 
explored using a stably transfected DHFR mutant with duplication of Exon-2 
of the dhfr gene that causes a frameshift abolishing DHFR activity. Chen and 
Chasin [32] developed this model generating NB6 cells, carrying that 
minigene with 2 Exons 2 of the dhfr gene (D22) (Fig. 8).  
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 Those cells are auxotrophic for glycine, hypoxanthine and thymidine. 
However, strategies that induce Exon-skipping of that minigene within NB6 
cells and recover prototrophy for one carbon metabolism. Therefore,                                                               
Exon-skipping can be positively detected and selected by growing                    
NB6 cells in –GHT medium. This approach was used to test the capability of 
PPRHs to cause Exon-skipping at the DNA level.  
 The sequence corresponding to the pD22 minigene was analyzed for 
polypurine target regions and the corresponding editing-PPRHs were 
designed, by attaching to the end of one strand of the PPRH core, a sequence 
tail homologous to the upstream and downstream regions of the PstI 
restriction site in the original dhfr minigene pDCH1P (Fig. 9).  
 
 
 
Figure 8. Structure of the pD22 dhfr minigene. The Chinese hamster dhfr minigene 
pDCHlP containing the six exons of the gene, intron 1, about 900 bp of the 5' flank, 
and the first of the two major polyadenylation sites in exon 6 was used to construct 
pD22 in which a 0.8-kb PstI-BstEII genomic DNA fragment containing exon 2 and 
flanks was cloned into the unique PstI site in intron 1 of pDCH1P. 
 
 
 
Figure 9. Structure of the different Editing-PPRH used to edit the extra exon 2 
present in the dhfr minigene pD22 stably transfected in NB6 cells. 
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 150,000 NB6 cells were plated and the corresponding editing-PPRHs 
were transfected using 2 to 5 µg of DNA. Random cell colonies surviving in 
–GHT medium from different experiments were expanded individually, and 
the targeted DNA region was PCR-amplified and sequenced. Cells were 
subsequently analyzed for DHFR protein, and enzyme activity levels. As it 
can be seen in Fig. 10, in all the clones analyzed, DHFR protein was 
restored, and it showed high levels of DHFR activity. Furthermore, the DNA 
sequencing results proved that the dhfr sequence in all the surviving clones 
corresponded to the wild type dhfr minigene with just one copy of Exon 2 
(data not shown). 
 
 
 
Figure 10. DHFR activity and protein levels. Experimental conditions as described. 
DHFR activity and protein levels in the edited colonies were compared to those of 
the control NB6-B cells.  
 
5. Conclusion 
 
 We provide evidences that repair-PPRHs have the ability to correct 
different types of mutations in mammalian cells. Therefore, our method may 
offer an alternative, simple, and powerful tool for gene therapy to correct 
many disorders caused by point mutations. In addition, we show that                   
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editing-PPRHs represent an alternative method to ZFN, TALEN and 
CRISPR/Cas9 site specific nucleases for efficient editing, without the 
difficulty in constructing and delivering exogenous enzymes, the off-target 
effect caused by the nucleases, and the non-homologous end joining effects 
stimulated after a DNA double strand break.  
 
Acknowledgements 
 
 The work was supported by Grants SAF2011-23582 and                    
SAF2014-51825-R from “Plan Nacional de Investigación Científica” 
(Spain). Our group holds the Quality Mention from the “Generalitat de 
Catalunya” 2014-SGR96. A.S. was recipient of a FI fellowship from the 
“Generalitat de Catalunya”. A.J. is recipient of a FPU fellowship from the 
“Ministerio de Educación”. 
 
References 
 
1.  Jackson, S.P., Bartek, J. 2009, Nature, 461, 1071.  
2.  Lodish, H,, Berk, A., Zipursky, L,, Matsudaira, P., Baltimore, D., Darnell, J. 
2004, Molecular Cell Biology, 4th Edition. 
3.  Luch, A. 2005, Discov Med, 5, 472.  
4.  Bernstein KA, Mimitou EP, Mihalevic MJ, Chen H, Sunjaveric I, Symington LS, 
Rothstein R. 2013, Genetics, 195,1241.  
5.  Canman, C.E., Lim, D.-S. 1999 Oncogene, 17, 3301.  
6.  Banin, S.., Moyal, L., Shieh, S., Taya, Y., Anderson, C.W., Chessa, L., 
Smorodinsky, N.I., Prives, C., Reiss, Y., Shiloh, Y., Ziv, Y.1998, Science, 
281,1674.  
7.  Tibbetts R.S., Brumbaugh, K.M., Williams, J.M., Sarkaria, J.N., Cliby, W.A., 
Shieh, S.Y., Taya, Y., Prives, C., Abraham, R.T.1999, Genes Dev, 13, 152.  
8.  Liu N, Bryant PE. 1994, Int J Radiat Biol, 66, S115.  
9.  Wiman KG. 2006, Cell Death Differ, 13, 921.  
10.  Martinho RG1, Lindsay HD, Flaggs G, DeMaggio AJ, Hoekstra MF, Carr AM, 
Bentley N.J.1998, EMBO J, 17, 7239. 
11.  Latif, C., Harvey, S.H., O’Connell, S.J. 2001, Sci World J , 1, 684.  
12.  Wyman, C., Kanaar, R. 2006, Annu Rev Genet, 40, 363.  
13.  Carroll, D., Beumer,  K.J. 2014, Methods, 69, 137.  
14.  Ochiai, H. 2015, Int J Mol Sci, 16, 21128.  
15.  Coma, S., Noe, V., Eritja, R., Ciudad, C. J.  2005, Oligonucleotides, 15, 269. 
16.  de Almagro, M. C., Coma, S., Noe, V., Ciudad, C. J.  2009, J. Biol. Chem., 284, 
11579. 
17.  de Almagro, M. C., Mencia, N., Noe, V., Ciudad, C. J.  2011 Hum. Gene Ther. 
2011, 22, 451. 
Carles Ciudad et al. 68 
18.  Rodriguez, L., Villalobos, X., Dakhel, S., Padilla, L., Hervas, R., Hernandez, J. L., 
Ciudad, C. J., Noe, V.  2013, Biochem. Pharmacol., 86, 1541.  
19.  Villalobos, X., Rodriguez, L., Prevot, J., Oleaga, C.; Ciudad, C. J.; Noe, V. 
2014, Mol.  Pharm., 11, 254. 
20.  Villalobos, X., Rodriguez, L., Sole, A., Lliberos, C., Mencia, N., Ciudad, C. J., 
Noe, V. 2015, Nucleic Acid Ther., 25, 198. 
21.  Sole, A., Villalobos, X., Ciudad, C. J., Noe, V. 2014, Hum. Gene Ther. Methods, 
25, 288. 
22.  Carothers, A. M., Urlaub, G., Steigerwalt, R. W., Chasin, L. A., Grunberger, D. 
1986, Proc Natl Acad Sci U S A, 83, 6519. 
23.  Urlaub, G., Mitchell, P. J., Ciudad, C. J., Chasin, L. A.1989, Mol. Cell. Biol.,                                              
9, 2868. 
24.  Chasin, L. A., Urlaub, G., Mitchell, P., Ciudad, C., Barth, J., Carothers, A. M., 
Steigerwalt, R., Grunberger, D. 1990, Prog. Clin. Biol. Res., 340A, 295. 
25.  Carothers, A. M., Urlaub, G., Grunberger, D., Chasin, L. A. 1993, Mol. Cell. 
Biol., 13, 5085. 
26.  Carothers, A. M., Urlaub, G., Mucha, J., Yuan, W., Chasin, L. A., Grunberger, 
D. 1993, Carcinogenesis, 14, 2181. 
27.  Urlaub, G., Kas, E., Carothers, A. M., Chasin, L. A. 1983, Cell, 33, 405. 
28.  Rodriguez, L., Villalobos, X., Sole, A., Lliberos, C., Ciudad, C. J., Noe, V. 
2015, Mol.  Pharm., 12, 867. 
29.  Solé, A., Ciudad, C.J., Chasin, L.A., Noé, V. 2016, Biochem Pharmacol,           
110–111, 16.  
30.  Douglas, A.G.L., Wood, M.J.A.  2013, Mol Cell Neurosci, 56, 169. 
31.  Echigoya, Y., Yokota, T. 2014, Nucleic Acid Ther, 24, 57. 
32.  Chen, I.T., Chasin, L.A. 1993, Mol Cell Biol, 13, 289.  
 
 
 
 
